Uploaded July 2026 | Updated September 2026, 3 weeks ago

---

Scribe Therapeutics has secured more than $25 million from the California Institute for Regenerative Medicine to advance two CRISPR-based gene therapies toward human trials. The one-time treatments target inherited cardiovascular risk factors, lipoprotein(a) (Lp(a)) and APOC3, aiming to reduce genetic drivers of heart disease that lifestyle changes alone cannot fully address.

Full Episode on YouTube, Spotify and Apple Podcast. Link in the comment.

#LongevityTechnologyUnlocked #LongevityPodcast #GeneTherapy #ScribeTherapeutics #CRISPR #HeartHealth